PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 296.7K (Avg.)
-1.36 | -1.31
Gauges a company's financial stability and solvency. Value investors pay close attention to leverage and liquidity risk, ensuring the company has enough cushion to withstand downturns without impairing shareholder value.
0.00
D/E of 0.00 while TRAW has all-equity financing. Bruce Berkowitz would demand higher returns to justify our leverage.
3.47
Higher net debt at 1.1-1.25x TRAW's 2.84. Bruce Berkowitz would look for hidden assets justifying this higher leverage.
-4767.88
Negative coverage while TRAW shows 0.00. Joel Greenblatt would look for operating improvements and turnaround potential.
8.59
Current ratio exceeding 1.5x TRAW's 2.76. Charlie Munger would verify if this advantage translates to better supplier terms.
No Data
No Data available this quarter, please select a different quarter.